Royce & Associates LP Acquires 238,956 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Key Points

• Royce & Associates LP drastically increased its holdings in Amphastar Pharmaceuticals, Inc. by 2,684.3% during the first quarter, acquiring an additional 238,956 shares to bring its total to 247,858 shares, valued at approximately $7.2 million.
• The stock of Amphastar Pharmaceuticals currently has a market capitalization of $1.05 billion and recently showed a decline of 0.6%, with its trading values reflecting a fifty-two week low of $20.43 and a high of $53.96.
• Equities research analysts have issued mixed ratings on Amphastar Pharmaceuticals, with a consensus rating of "Hold" and an average target price of $32.33, down from previous estimates.

Royce & Associates LP lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 2,684.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 247,858 shares of the company's stock after acquiring an additional 238,956 shares during the period. Royce & Associates LP owned approximately 0.52% of Amphastar Pharmaceuticals worth $7,185,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Signaturefd LLC increased its position in shares of Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after purchasing an additional 520 shares in the last quarter. IFP Advisors Inc acquired a new stake in shares of Amphastar Pharmaceuticals during the 1st quarter worth about $34,000. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals during the 4th quarter worth about $38,000. GAMMA Investing LLC increased its position in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after purchasing an additional 424 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Stock Down 0.6%

Amphastar Pharmaceuticals stock opened at $22.37 on Friday. The company's 50 day simple moving average is $24.01 and its 200 day simple moving average is $27.24. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.43 and a fifty-two week high of $53.96. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 8.11 and a beta of 0.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.